Syn-Med-Chemist

Syn-Med-Chemist-"Quintessential Synthetic Chemistry"---A Synthetic Chemist's Perception......

Monday, December 1, 2014

Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in Psoriatic Arthritis and Ankylosing Spondylitis

Novartis to present first IL-17A Phase III data for AIN457 (secukinumab) in Psoriatic Arthritis and Ankylosing Spondylitis
Posted by https://www.med-chemist.com at 5:15 AM

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Proud Indian

Proud Indian
Indian Flag

My other blogs

  • Nanotechnology - Technology for every facet of life
  • Med-Chemist : "Quintessential Medicinal Chemistry" - A Medicinal Chemist's Perception...

Tell A Friend

BuzzBoost

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

My Blog List

Visitors Map

Map IP Address
Powered byIP2Location.com

Followers

Blog Archive

  • ►  2016 (27)
    • ►  July (2)
    • ►  June (1)
    • ►  May (2)
    • ►  April (9)
    • ►  March (5)
    • ►  February (2)
    • ►  January (6)
  • ►  2015 (79)
    • ►  December (13)
    • ►  November (3)
    • ►  October (14)
    • ►  September (2)
    • ►  August (1)
    • ►  June (3)
    • ►  May (10)
    • ►  April (11)
    • ►  March (6)
    • ►  February (5)
    • ►  January (11)
  • ▼  2014 (43)
    • ▼  December (18)
      • Multiple micronutrients for pregnant women does no...
      • Kinex Pharmaceuticals doses first patient with KX2...
      • Drugs delay disease progression for women with hor...
      • New study reveals how COX-2 inhibitors can increas...
      • Drugs delay disease progression for women with hor...
      • PD-L1 expression tied to favourable prognosis in SCLC
      • Researchers develop new method to track movement o...
      • MorphoSys, Xencor announce final results from MOR2...
      • TWi Biotechnology gets approval of Phase II clinic...
      • Spinach chlorophyll activates polymer production line
      • Findings may guide doctors to choose better therap...
      • Prolongz drug achieves No. 1 spot in the personal ...
      • Non-ergot derived dopamine agonists may be safe fo...
      • Experimental Cholesterol-Lowering Drug Effective, ...
      • Research findings may lead to new ways to thwart d...
      • Study suggests Golgi as potential drug target for ...
      • Researchers discover why advanced melanoma patient...
      • Novartis to present first IL-17A Phase III data fo...
    • ►  November (9)
    • ►  October (8)
    • ►  September (8)
  • ►  2011 (6)
    • ►  September (1)
    • ►  August (3)
    • ►  January (2)
  • ►  2010 (10)
    • ►  December (2)
    • ►  November (1)
    • ►  September (1)
    • ►  July (2)
    • ►  May (1)
    • ►  April (1)
    • ►  February (1)
    • ►  January (1)
  • ►  2009 (5)
    • ►  December (1)
    • ►  November (1)
    • ►  October (1)
    • ►  June (1)
    • ►  January (1)
  • ►  2008 (3)
    • ►  December (3)

About Me

My photo
https://www.med-chemist.com
View my complete profile
Add to Technorati Favorites
Picture Window theme. Powered by Blogger.